Mélanie Vivancos

Mélanie Vivancos

Auto-generated profile, based on publicly available information

Mélanie Vivancos

Clinical Research and Innovation Department, Infirmerie Protestante, Caluire-et-Cuire, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMarc Sousbie
Marc Sousbie
MVMélanie Vivancos
Mélanie Vivancos
RBRebecca Brouillette
Rebecca Brouillette
Elie Besserer-OffroyElie Besserer-Offroy
Elie Besserer-Offroy
JLJean-Michel Longpré
Jean-Michel Longpré
ÉMÉric Marsault
Éric Marsault

1 May 2021 in Behavioural Brain Research
Verified
Journal Article
Closed access
MVMélanie Vivancos
Mélanie Vivancos
RFRoberto Fanelli
Roberto Fanelli
Elie Besserer-OffroyElie Besserer-Offroy
Elie Besserer-Offroy
SBSabrina Beaulieu
Sabrina Beaulieu
MCMagali Chartier
Magali Chartier
PSPhilippe Sarret
Philippe Sarret

11 April 2025 in JMIR Formative Research
Verified
Journal Article
Open access
OROlivier Raspado
Olivier Raspado
MBMichel Brack
Michel Brack
OBOlivier Brack
Olivier Brack
MVMélanie Vivancos
Mélanie Vivancos
AEAurélie Esparcieux
Aurélie Esparcieux
AAAbdellah Aouifi
Abdellah Aouifi
Background: Serious pulmonary pathologies of infectious, viral, or bacterial origin are accompanied by inflammation and an increase in oxidative stress (OS). In these situations, biological measurements of OS are technically difficult to obtain, and their results are difficult to interpret. OS assays that do not require complex preanalytical methods, as well as machine learning methods for improving interpretation of the results, would be very useful tools for medical and care teams. Objective: We aimed to identify relevant OS biomarkers associated with the severity of hospitalized patients’ condition and identify possible correlations between OS biomarkers and the clinical status of hospitalized patients with COVID-19 and severe lung disease at the time of hospital admission. Methods: All adult patients hospitalized with COVID-19 at the Infirmerie Protestante (Lyon, France) from February 9, 2022, to May 18, 2022, were included, regardless of the care service they used, during the respiratory infectious COVID-19 epidemic. We collected serous biomarkers from the patients (zinc [Zn], copper [Cu], Cu/Zn ratio, selenium, uric acid, high-sensitivity C-reactive protein [hs-CRP], oxidized low-density lipoprotein, glutathione peroxidase, glutathione reductase, and thiols), as well as demographic variables and comorbidities. A support vector machine (SVM) model was used to predict the severity of the patients’ condition based on the collected data as a training set. Results: A total of 28 patients were included: 8 were asymptomatic at admission (grade 0), 14 had mild to moderate symptoms (grade 1) and 6 had severe to critical symptoms (grade 3). As the first outcome, we found that 3 biomarkers of OS were associated with severity (Zn, Cu/Zn ratio, and thiols), especially between grades 0 and 1 and between grades 0 and 2. As a second outcome, we found that the SVM model could predict the level of severity based on a biological analysis of the level of OS, with only 7% misclassification on the training dataset. As an illustrative example, we simulated 3 different biological profiles (named A, B, and C) and submitted them to the SVM model. Profile B had significantly high Zn, low hs-CRP, a low Cu/Zn ratio, and high thiols, corresponding to grade 0. Profile C had low Zn, low selenium, high oxidized low-density lipoprotein, high glutathione peroxidase, a low Cu/Zn ratio, and low glutathione reductase, corresponding to grade 2. Conclusions: The level of severity of pulmonary damage in patients hospitalized with COVID-19 was predicted using an SVM model; moderate to severe symptoms in patients were associated with low Zn, low plasma thiol, increased hs-CRP, and an increased Cu/Zn ratio among a panel of 10 biomarkers of OS. Since this panel does not require a complex preanalytical method, it can be used and studied in other pathologies associated with OS, such as infectious pathologies or chronic diseases.

15 September 2024 in JMIR Preprints
Verified
Preprint
Open access
OROlivier Raspado
Olivier Raspado
MBMichel Brack
Michel Brack
OBOlivier Brack
Olivier Brack
MVMélanie Vivancos
Mélanie Vivancos
AEAurélie Esparcieux
Aurélie Esparcieux
AAAbdellah Aouifi
Abdellah Aouifi
BACKGROUND Oxidative Stress (OS) is an imbalance between the production of free radicals and the body's ability to neutralize them, leading to damages of cells, proteins and deoxyribonucleic. OBJECTIVE To identify the relevant biomarkers of OS which could be associated to severity of hospitalized patients and to identify a possible correlation between OS biomarkers and clinical status of hospitalized COVID-19 patients with severe lung disease at hospital admission. METHODS All adult patients hospitalized with COVID-19 at the Infirmerie Protestante (Lyon, France) from 9th February 2022 to 18th May 2022 were included, regardless of the care service. The final sample consisted in 28 patients. Ten biomarkers were collected per patient (Zinc (Zn), Copper (Cu), Cu/Zn, Selenium, Uric acid, CRplus, Oxidized LDL, Glutathione peroxidase, Glutathione reductase and Thiols), as well as demographic variables and comorbidities. A support vector machine (SVM) model was used to predict the severity grade per patient, based on the collected data as training set. RESULTS : Three biomarkers of OS were associated with severity; Zn, Cu/Zn and Thiols especially for grade 0 (asymptomatic) and grade 1 (mild to moderate severity). The SVM model predicted the level of severity from the biological analysis of the OS biomarkers with only 7.14% of discrepancy in the training dataset. CONCLUSIONS In case of COVID-19 infection, moderate to severe symptomatic patients are associated with a lowered zinc level, a lowered plasma thiol level, an increased CRPus and an increased Cu/Zn ratio among a panel of ten biomarkers of OS.